Alkermes logo

Alkermes

ALKS | NASDAQ
Chart Builder DCF Calculator
$46.53
-$0.50 (-1.06%)
At close: Nov 16, 2026, 4:00 PM ET
$46.53
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-1.06%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
29.8
-0.1 pts
Fundamentals Weak
Market Sentiment Bullish
Moat Narrow
Sector Rank #804/1021 (Top 79%)

Key Statistics

Market Data

Market Cap $7.82B
1D Range
46.26 47.76
52W Range
27.20 55.22

Valuation (TTM)

PE -2.74K
PB 4.19
EV/EBITDA 48.33

Valuation (NTM)

Forward PE 81.95
Forward PEG -120.36
Price Target $58.50
Loading financial charts...

Profile

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the...

Sector Healthcare
Employees 2,050
IPO Date Jul 16, 1991
Fiscal Year January - December

Latest News

Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead

21 hours ago · marketbeat.com

Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress

12 days ago · businesswire.com

Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript
What Alkermes (ALKS) Said on Its Q3 Earnings Call

14 days ago · marketbeat.com

What Alkermes (ALKS) Said on Its Q3 Earnings Call
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say

14 days ago · zacks.com

Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates

14 days ago · zacks.com

Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Alkermes plc Reports Third Quarter 2026 Financial Results

14 days ago · businesswire.com

Alkermes plc Reports Third Quarter 2026 Financial Results
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

18 days ago · businesswire.com

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story

18 days ago · seekingalpha.com

Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
Alkermes to Report Third Quarter Financial Results on November 3, 2026

27 days ago · businesswire.com

Alkermes to Report Third Quarter Financial Results on November 3, 2026

Earnings

Latest Earnings
Nov 3, 2026
EPS
$0.09
Beat +210.09%
REV
$480.13M
Beat +3.59%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
13
Consensus
Buy
Price Target
$58.50
Upside
+25.73%
Buy (10)
Hold (2)
Sell (1)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.